Apnimed Stock Jumps After BofA and Cantor Kick Off Coverage with Big Upside Targets

BofA and Cantor Fitzgerald initiate coverage on Apnimed with Buy and Overweight ratings for Oxnimbi, its oral therapy for obstructive sleep apnea.